Senseonics posted Q4 2025 total revenue of USD 14.3 million, up 72% YoY, including USD 12.1 million in the U.S. and USD 2.2 million outside the U.S. Q4 gross profit was USD 7.7 million, while net loss was USD 20.8 million (loss per share: USD 0.46). R&D expense in Q4 was USD 8.8 million and SG&A expense was USD 19.8 million. For FY 2025, Senseonics reported total revenue of USD 35.3 million, up 57% YoY, with U.S. revenue of USD 27.9 million and revenue outside the U.S. of USD 7.4 million. FY gross profit was USD 15.8 million, and net loss was USD 69.1 million (loss per share: USD 1.66). Cash, cash equivalents and investments totaled USD 94.3 million at Dec. 31, 2025, and outstanding indebtedness was USD 35.3 million. During the period, the company received CE Mark approval for Eversense 365 in the EU, launched the twiist automated insulin delivery system integration with Eversense 365 in the U.S., secured FDA IDE approval and enrolled first patients in the Gemini sensor pivotal trial (expected to complete in H2 2026), and executed agreements with Ascensia Diabetes Care to take back Eversense commercialization and distribution starting Jan. 1, 2026. Senseonics guided FY 2026 global net revenue of about USD 58 million to USD 62 million and gross margin of about 50%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603021601PRIMZONEFULLFEED9664246) on March 02, 2026, and is solely responsible for the information contained therein.
Comments